Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Champions Oncology (CSBR) Gross Margin (2016 - 2026)

Champions Oncology has reported Gross Margin over the past 17 years, most recently at 83.9% for Q1 2026.

  • For Q1 2026, Gross Margin rose 2273.0% year-over-year to 83.9%; the TTM value through Jan 2026 reached 67.12%, down 2259.0%, while the annual FY2025 figure was 50.15%, 3577.0% down from the prior year.
  • Gross Margin for Q1 2026 was 83.9% at Champions Oncology, up from 51.7% in the prior quarter.
  • Over five years, Gross Margin peaked at 207.75% in Q2 2024 and troughed at 46.52% in Q2 2022.
  • A 5-year average of 62.48% and a median of 49.7% in 2024 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: soared 16389bps in 2024 and later crashed -16660bps in 2025.
  • Year by year, Gross Margin stood at 47.88% in 2022, then fell by -11bps to 42.82% in 2023, then grew by 5bps to 44.93% in 2024, then increased by 15bps to 51.7% in 2025, then skyrocketed by 62bps to 83.9% in 2026.
  • Business Quant data shows Gross Margin for CSBR at 83.9% in Q1 2026, 51.7% in Q4 2025, and 86.75% in Q3 2025.